Corbus Pharmaceuticals (CRBP) announced the dosing of the first subject in the single ascending dose / multiple ascending dose portion of the Phase 1 trial of CRB-913 for the treatment of obesity ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP slipped 4.66% to $5.52 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a biopharmaceutical company with a market capitalization of $77 million, announced on Monday the appointment of Ian Hodgson as the new Chief ...

NORWOOD, Mass. (AP) — NORWOOD, Mass. (AP) — Corbus Pharmaceuticals Holdings Inc. (CRBP) on Tuesday reported a loss of $9.5 million in its fourth quarter. The Norwood, Massachusetts-based ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a biopharmaceutical company currently valued at $71 million, announced on Thursday that Dr. Peter Salzmann has decided not to seek re-election ...

NASDAQ CRBP opened at $6.79 on Thursday. Corbus Pharmaceuticals has a 12 month low of $6.54 and a 12 month high of $61.90. The stock’s fifty day moving average price is $9.98 and its 200-day ...

NORWOOD, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a biopharmaceutical company currently valued at $71 million, announced on Thursday that Dr. Peter Salzmann has decided not to seek re-election to ...